IP Library Granted Patent US 9,597,368
Granted Patent B2
US 9,597,368 · App. 14/370,881 · Granted Mar 21, 2017

Peptide and uses therefor

Inventors: George Edward Rainger (Worcestershire, GB); Parth Narendran (Birmingham, GB); Helen McGettrick (Birmingham, GB); Myriam Chimen (Birmingham, GB)
Assignee: The University of Birmingham
A61K38/10A61K38/1709
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,597,368
App. No.
14/370,881
Granted
Mar 21, 2017
Kind
B2
Abstract

Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N′-SVTEQGAELSNEER-C′ (SEQ ID NO: 1) or an analog of the peptide that inhibits T cell migration. Also provided is the peptide or its analog for use in the methods of treatment and/or prophylaxis of the condition.

Claims (9)

1. A method for treatment of a T-cell mediated autoimmune disease, comprising administering to a patient in need thereof:

a peptide consisting of no more than 20 amino acids and comprising N′-SVTEQGAELSNEER-C′ (SEQ ID NO: 1) or an analogue or variant thereof that inhibits T cell migration; or

a chimeric or fusion protein comprising said peptide,

wherein the disease is selected from the group consisting of diabetes mellitus (type 1), rheumatoid arthritis, Crohn's disease and uveitis.

2. The method according to claim 1 , wherein the disease is diabetes mellitus (type 1).

3. The method according to claim 1 , wherein the migration of the T cells is trans-endothelial across the endothelium of the pancreatic microvasculature separating the islet cells from the blood supply.

4. The method according to claim 1 , wherein the T cells are auto-reactive T cells.

5. The method according to claim 4 , wherein the peptide serves to inhibit the recruitment of auto-reactive T cells to the islets of the pancreas.

6. The method according to claim 1 , wherein the peptide, analogue, variant, or chimeric or fusion protein thereof as defined in claim 1 is administered in the form of a pharmaceutically acceptable composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: RAINGER, GEORGE EDWARD; NARENDRAN, PARTH; MCGETTRICK, HELEN; CHIMEN, MYRIAM
To: THE UNIVERSITY OF BIRMINGHAM
Reel/Frame 034187/0947 →
Priority Claims (1)
GB 1200555.9 · Jan 13, 2012 · national
Continuity (1)
Related Publication 20150051137A1 · Feb 19, 2015